Avalo Therapeutics AVTX

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.45 (+6.14%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Avalo Therapeutics (AVTX)
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $7.76

  • Market Cap

    $81.48 Million

  • Price-Earnings Ratio

    7.92

  • Total Outstanding Shares

    10.46 Million Shares

  • Total Employees

    19

  • Dividend

    No dividend

  • IPO Date

    November 13, 2015

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    540 gaither road, Rockville, MD, 20850

  • Homepage

    https://www.avalotx.com

Historical Stock Splits

If you bought 146,880 shares of AVTX before September 10, 2007, you'd have 1 share today.
Execution DateSplit Amount
December 29, 20231-for-240 (Reverse Split)
July 8, 20221-for-12 (Reverse Split)
September 10, 20071-for-51 (Reverse Split)

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$0
Net Cash Flow From Operating Activities, Continuing$-11.53 Million
Net Cash Flow From Operating Activities$-11.53 Million
Net Cash Flow, Continuing$-11.53 Million
Net Cash Flow From Investing Activities, Continuing$0
Net Cash Flow From Investing Activities$0

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Cost Of Revenue$-714,000
Preferred Stock Dividends And Other Adjustments$17.57 Million
Undistributed Earnings/Loss Allocated To Participating Securities, Basic$17.57 Million
Nonoperating Income/Loss$35.88 Million
Gross Profit$963,000
Basic Average Shares$5.55 Million

Comprehensive Income

July 1, 2024 to September 30, 2024
MetricValue
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss$23.04 Million
Other Comprehensive Income/Loss$0
Comprehensive Income/Loss Attributable To Parent$23.04 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Current Assets$86.15 Million
Equity$21.08 Million
Accounts Payable$1.81 Million
Noncurrent Liabilities$15.05 Million
Assets$98.45 Million
Other Current Liabilities$56.67 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about AVTX from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.